Search

everythinglearnresearchcommunity

for

Search:↓

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Methotrexate, resveratrol, and curcumin may help treat alopecia areata by targeting immune cells.

Sparse hairless patches can develop and stabilize in alopecia areata under certain conditions.

Fetal skin has unique immune cells different from adult skin.

A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.

An 8-year-old girl developed a rare skin condition in a linear pattern on one side of her body after a lung infection, which improved with treatment.

New treatments for the autoimmune hair loss condition alopecia areata may include JAK inhibitors and other immunomodulators.

Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.

Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.

taVNS reduces vitiligo symptoms in mice.

Assessing CD8+ T cell levels before surgery may improve vitiligo treatment outcomes.

Mitochondrial stress can lead to atopic dermatitis.

ILC1-like cells can cause alopecia areata by themselves.

Thymoma with alopecia areata may be linked to abnormal immune cells.

Mogamulizumab can cause hair loss, often linked to a better treatment response.

Different immune responses cause hair loss in scalp diseases, with unique patterns in scalp psoriasis possibly protecting against hair loss.

Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.

The humanized AA mouse model is better for testing new alopecia areata treatments.

JAK inhibitors and combination therapies show promise for treating severe alopecia areata.

PCOS involves immune and genetic factors, with key roles for T cells and specific genes.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Exosomes from certain cells can improve hair regrowth by changing the immune response.

The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.

PCOS involves genetic and immune factors, especially T cells, affecting its development.

Restoring hair follicle immune privilege may help treat alopecia areata.

Targeting gut microbiome and metabolome may help treat autoimmune skin diseases like alopecia areata.

Reducing CD8+ T cell growth can stabilize alopecia areata.

CS12192 effectively treats alopecia areata with better safety than current options.

RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.